Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Consumer OTC Drugs

Wyeth’s Alavert, Protonix Sales Suffer Under Generic Pressures

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Sales of Wyeth's Alavert non-sedating antihistamine declined in the third quarter due to an unfavorable comparison with the product's year-ago launch period

You may also be interested in...



Prilosec OTC Sales Top The $400 Mil. Mark; Prevacid Feeling The Burn

Abbott says that Prilosec OTC continues to eat into Prevacid sales and the overall prescription proton pump inhibitor category after one year on the market

AstraZeneca Nexium Ad Campaign May Try To Up-Sell Prilosec OTC Patients

AstraZeneca is considering development of a direct-to-consumer ad campaign for Nexium that would target Prilosec OTC users

Wyeth Kids Around With Dimetapp, Advil, Alavert Line Extensions

Wyeth Consumer Healthcare unveiled a series of new allergy and cold products aimed at children at the recent National Association of Chain Drug Stores Marketplace in San Diego June 21-24

Table

View full table

Topics

Tags:
Consumer OTC Drugs
Latest Headlines

CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings

Medicare Reimbursement For Part B Drugs Is 48% Above 340B Prices To Hospitals, MedPAC Finds

Drug Shortages, Inspections In Focus At US FDA Appropriations Hearing

Global Pharma Guidance Tracker – March 2024

See All
UsernamePublicRestriction

Register

PS097440

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By